Financial Performance - The company's operating revenue for Q1 2025 was ¥997,091,245.37, a decrease of 14.99% compared to ¥1,172,923,244.52 in the same period last year[5]. - The net loss attributable to shareholders was ¥106,353,858.88, slightly worsening by 1.37% from a loss of ¥104,912,277.28 in the previous year[5]. - Total operating revenue for the current period was ¥997,091,245.37, a decrease of approximately 15% from ¥1,172,923,244.52 in the previous period[17]. - Net loss for the current period was ¥132,959,986.79, compared to a net loss of ¥131,877,100.92 in the previous period, indicating a slight increase in losses[18]. - Total comprehensive income for the period was -132,959,986.79, compared to -131,877,100.92 in the previous period, indicating a slight increase in losses[19]. - Basic and diluted earnings per share were both -0.0471, slightly worse than -0.0464 in the previous period[19]. Cash Flow - The net cash flow from operating activities increased by 11.20% to ¥243,804,159.36, compared to ¥219,246,919.94 in the same period last year[5]. - Net cash flow from operating activities was 243,804,159.36, an increase from 219,246,919.94 in the previous period[21]. - Cash inflow from operating activities totaled 1,076,605,731.63, down from 1,221,898,669.41 in the previous period[20]. - Cash outflow from operating activities was 832,801,572.27, compared to 1,002,651,749.47 in the previous period[21]. - Net cash flow from investing activities was -71,687,778.63, an improvement from -137,436,233.21 in the previous period[21]. - Cash inflow from financing activities was 99,980,000.00, down from 199,400,000.00 in the previous period[21]. - Net cash flow from financing activities was -351,075,002.20, worsening from -283,609,925.44 in the previous period[21]. - The ending cash and cash equivalents balance was 369,603,381.91, down from 742,163,400.11 in the previous period[21]. Assets and Liabilities - The total assets at the end of the reporting period were ¥10,318,842,882.85, down 2.98% from ¥10,636,321,992.89 at the end of the previous year[5]. - Total assets decreased to ¥10,318,842,882.85 from ¥10,636,321,992.89, a reduction of approximately 3%[15]. - Current liabilities totaled ¥4,075,263,256.04, down from ¥4,151,485,482.84, representing a decrease of about 2%[15]. - Non-current liabilities decreased to ¥2,904,549,572.58 from ¥3,012,846,469.03, a decline of approximately 4%[15]. - The company's total equity decreased to ¥3,339,030,054.23 from ¥3,471,990,041.02, indicating a decline of approximately 4%[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 109,907, with the largest shareholder holding 27.25% of the shares[10]. Other Information - Non-recurring gains and losses amounted to ¥13,392,880.03, primarily from government subsidies and fair value changes of financial assets[6]. - The company reported a significant reduction in credit impairment losses by 423.78% compared to the previous year, indicating improved asset quality[8]. - The company has not disclosed any new product developments or market expansion strategies in this report[5]. - The company's weighted average return on equity was -2.94%, a decrease of 0.22% from -2.72% in the previous year[5]. - The company's cash and cash equivalents decreased to ¥471,603,381.91 from ¥590,562,003.38, a drop of about 20%[13]. - Accounts receivable decreased to ¥690,857,166.93 from ¥739,394,118.00, reflecting a decline of approximately 7%[13]. - Inventory decreased to ¥63,274,718.58 from ¥81,005,105.26, a reduction of about 22%[14]. - The company’s first quarter report was not audited[23].

Financial Performance - The company's operating revenue for 2024 was CNY 4,815,466,752.34, representing a 4.28% increase from CNY 4,617,873,479.43 in 2023[20] - The net profit attributable to shareholders for 2024 was a loss of CNY 254,128,508.13, an improvement of 31.01% compared to a loss of CNY 368,360,645.24 in 2023[20] - The net cash flow from operating activities decreased by 7.19% to CNY 1,009,119,813.21 from CNY 1,087,334,386.41 in the previous year[20] - The total assets at the end of 2024 were CNY 10,636,321,992.89, down 6.05% from CNY 11,321,135,811.77 at the end of 2023[20] - The net assets attributable to shareholders decreased by 5.96% to CNY 3,674,927,755.19 from CNY 3,908,017,195.19 in 2023[20] - The basic earnings per share improved to -CNY 0.11 from -CNY 0.16 in 2023, reflecting a 31.25% increase[20] - The weighted average return on equity improved to -6.76% from -9.03% in the previous year, indicating a positive trend[20] Strategic Development - The company has undergone a strategic transformation focusing on healthcare services and modern medical technology applications since 2018[19] - The company is positioned to benefit from the ongoing healthcare reforms and increasing demand for high-quality medical services in China[34] - The company aims to enhance its core competitiveness through a "comprehensive medical + specialty" model, focusing on the integration of online and offline services[144] - The company plans to improve its medical service system through institutional innovation, management reform, and technological updates by 2025[145] - The company aims to enhance patient experience by implementing a full-cycle service upgrade plan and integrating online and offline services[153] Healthcare Market Insights - The average healthcare expenditure per capita in 2024 was ¥2,547, a 3.6% increase from the previous year, indicating rising healthcare demand[32] - The elderly population (60 years and above) in China reached 31,031 million in 2024, accounting for 22% of the total population, highlighting the growing market for healthcare services[32] - The silver economy market in China is estimated to be around ¥7 trillion, representing 6% of the GDP, with significant growth potential projected for the coming decades[33] - The healthcare industry in China is expected to grow significantly due to an aging population (14.8% aged 65 and above) and a high prevalence of chronic diseases (over 300 million patients)[142] Operational Highlights - The company operates two major hospitals: Xi'an High-tech Hospital and Xi'an International Medical Center Hospital, with a focus on comprehensive medical services and specialized departments[38] - The company has established a high-level medical health service platform covering the entire life cycle, with a growing influence in the healthcare industry[39] - The company provided outpatient services totaling 2.5727 million visits, a year-on-year increase of 7.70%, and inpatient services of 205,700 visits, a year-on-year increase of 10.73%[42] - The company has successfully implemented a "comprehensive medical + specialty" business model, addressing diverse healthcare needs and enhancing service quality[40] Research and Development - The company approved 54 national and provincial-level research projects, published 122 SCI papers, and authorized 58 patents during the year[63] - The hospital published 66 academic papers in 2024, including 22 SCI papers and 18 core journal papers, and was granted 2 patents[72] - The hospital achieved a breakthrough in research with 48 projects approved, including 1 national natural science fund project, marking a new level of research strength[87] Governance and Management - The company adheres to legal regulations and continuously improves its corporate governance structure, ensuring compliance with relevant laws and regulations[183] - The company maintains independence from its controlling shareholder in business operations, personnel, assets, and finances[183] - The board consists of 9 members, including 3 independent directors, ensuring compliance with legal requirements[184] - The company emphasizes transparency in information disclosure, ensuring all shareholders have equal access to information[186] Future Plans - The company plans to enhance its core competitiveness by accelerating the construction of new medical projects and improving overall medical service and health management levels[178] - The company aims to establish a "data-driven, process-controlled" evaluation management system by 2025, focusing on enhancing data quality control and ensuring accurate multi-platform data reporting[159] - The company will explore the application of large model technology in medical quality management and cost control, aiming for real-time error correction in quality control processes[162]

Company Overview - International Medical's closing price on April 17 was 5.3 yuan, an increase of 1.53%, with a latest price-to-book ratio of 3.28 and a total market capitalization of 11.98 billion yuan [1] - As of September 30, 2024, the number of shareholders reached 107,360, an increase of 3,652 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in health care services and the application of modern medical technology, with main products including medical services, software, and information technology services [1] Performance Metrics - For the third quarter of 2024, the company reported revenue of 3.606 billion yuan, a year-on-year increase of 7.85%, while net profit was -212.11 million yuan, a year-on-year decrease of 4.59%, with a gross profit margin of 9.19% [1] - The company's price-to-earnings (P/E) ratio (TTM) is -33.45, and the static P/E ratio is -32.52, with a price-to-book ratio of 3.28 [2] - The industry average P/E ratio is 45.40 (TTM) and 42.22 (static), with an average market capitalization of 14.162 billion yuan [2] Industry Comparison - The median P/E ratio in the industry is 47.48 (TTM) and 35.52 (static), with a median market capitalization of 4.862 billion yuan [2] - Other companies in the industry, such as Puri Eye Hospital and He’s Eye Hospital, have significantly higher negative P/E ratios, indicating potential challenges in profitability compared to International Medical [2]

海凭集团董事长宋广征介绍中国医疗器械产业发展趋势与合作机遇。他表示，海凭集团济南园是集团事 业发展的重中之重，是集团在北方布局的医疗器械产业基地。济南国际医学中心具有全国独一无二的医 教研产养服"六位一体"的综合发展业态，将为医疗器械企业提供高端研发服务、便捷审批渠道、丰富应 用场景、人才智力支持，全方位助力企业腾飞发展。 齐鲁晚报齐鲁壹点记者李培乐 近日，值第91届中国国际医疗器械博览会(CMEF)在上海召开之际，由济南国际医学（000516）中心管 委会主办、海凭国际.济南医疗器械产业园承办的济南国际医学中心医疗器械产业政策推介及项目招商 会成功举办，吸引了上百位医疗行业嘉宾到场共洽商机。 会上，济南国际医学中心管委会副主任徐强详细介绍了济南国际医学中心的产业发展情况，以及为医疗 器械产业提供的优惠政策，包括资金奖励、产品注册、创新研发、人才引进等方面的具体措施，旨在吸 引更多优质医疗器械企业入驻。医学中心愿与各方企业联手实现共建共享共赢，共同推动山东医疗器械 产业的快速发展。 推介会邀请了上海同济大学医学院副教授陈炳地、美国菲士公司中国区CEO姚志芹、欧姆龙医疗器械公 司销售总监杜聪等业内专家，分别就" ...

4月9日，国际医学今日收盘5.19元，上涨2.77%，最新市净率3.21，总市值117.31亿元。 截至2024年三季报，共有55家机构持仓国际医学，其中基金55家，合计持股数4299.13万股，持股市值 2.27亿元。 西安国际医学投资股份有限公司主营业务是大健康医疗服务和现代医学技术转化应用。主要产品是医 疗、软件和信息技术服务。经过全体国际医学人的共同努力，公司及子公司先后荣获"第四届'三秦善 星'爱心企业""西安市爱国拥军单位""第十八届金圆桌优秀董事会""2023年品牌民营医院""国际医疗旅游 试点示范基地""投资者关系管理工作优秀单位"等众多荣誉。 最新一期业绩显示，2024年三季报，公司实现营业收入36.06亿元，同比7.85%；净利润-212108983.83 元，同比4.59%，销售毛利率9.19%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)7国际医学-32.76-31.853.21117.31亿行业平均 45.7741.333.33140.72亿行业中值43.7835.472.4544.48亿1普瑞眼科-192.3424.042.9064.41亿2何氏眼 科-144.5344 ...

证券代码：000516 证券简称：国际医学 公告编号：2025-007 重要内容提示： 1、为响应国家对上市公司回购股票的支持政策，进一步提升资 金使用效率，西安国际医学投资股份有限公司（以下简称"公司"或 "国际医学"）拟将回购股份资金来源由"自有资金"调整为"自有 资金和股票回购专项贷款资金"。 除上述调整外，回购股份方案的其他内容未发生变化。 2、本次调整回购股份资金来源事项已经公司第十三届董事会第 四次会议决议通过，无需提交股东大会审议。 西安国际医学投资股份有限公司 关于调整回购股份资金来源暨取得金融机构 股票回购专项贷款承诺函的公告 本公司及董事会全体成员保证公告内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 3、本次股票回购专项贷款额度不代表公司对回购金额的承诺， 具体回购公司股份的金额以回购完毕或回购实施期限届满时公司的 实际回购情况为准。 一、回购股份的基本情况 公司于 2024 年 4 月 24 日召开第十二届董事会第十五次会议，并 1 二、回购股份进展情况 截至2025年3月31日，公司累计通过深圳证券交易所交易系统以 集中竞价交易方式回购公司股份10,997,100股, ...

除上述调整外，回购股份方案的其他内容未发生变化。根据《上 市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 1 本公司及董事会全体成员保证公告内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司董事会于 2025 年 4 月 7 日以书 面方式发出召开公司第十三届董事会第四次会议的通知，并于 2024 年 4 月 8 日以通讯表决方式召开。会议应参加表决董事 9 人，实际参 加表决的董事 9 人。会议的召开符合有关法律、法规、规章和《公司 章程》的规定。 经会议认真审议和投票表决，通过了下述决议： 通过《关于调整回购股份资金来源的议案》（9 票同意、0 票反 对、0 票弃权）； 证券代码：000516 证券简称：国际医学 公告编号：2025-006 西安国际医学投资股份有限公司 第十三届董事会第四次会议决议 公 告 为进一步提升资金使用效率，充分利用国家对上市公司回购股票 的支持政策，积极推进公司股份回购方案的实施，同意将回购股份方 案中的回购股份资金来源由"自有资金"调整为"自有资金和股票回 购专项贷款资金"。 2 号——回购股份》及《公司章程》的相关规 ...

截至2025年4月3日收盘，国际医学(000516)报收于5.6元，上涨1.08%，换手率0.85%，成交量18.98万 手，成交额1.06亿元。 公司公告汇总 西安国际医学投资股份有限公司于2024年4月24日召开第十二届董事会第十五次会议，并于2024年5月20 日召开2023年度股东大会，审议通过了关于回购公司股份方案的议案。公司决定使用自有资金以集中竞 价交易方式回购已发行的人民币普通股（A股）股票，回购的股份将全部用于注销以减少公司注册资 本。回购资金总额不低于人民币10,000万元且不超过人民币15,000万元，回购价格不超过人民币9.16元/ 股，回购期限为自公司股东大会审议通过本次回购方案之日起12个月内。 截至2025年3月31日，公司累计通过深圳证券交易所交易系统以集中竞价交易方式回购公司股份 10,997,100股，占公司当前总股本的0.4865%，最高成交价5.618元/股，最低成交价4.61元/股，成交总金 额57,426,831.72元（不含交易费用）。上述回购进展符合相关法律法规及公司既定的股份回购方案的规 定。公司回购股份的时间、数量及集中竞价交易的委托时段等均符合《上市公司股 ...

证券代码：000516 证券简称：国际医学 公告编号：2025-005 西安国际医学投资股份有限公司 关于股份回购进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 二、其他说明 西安国际医学投资股份有限公司（以下简称"本公司"或"公司"） 于2024年4月24日召开第十二届董事会第十五次会议，并于2024年5月20 日召开2023年度股东大会，审议通过了《关于回购公司股份方案的议案》 及《关于提请股东大会授权董事会办理本次回购相关事宜的议案》，决 定使用自有资金以集中竞价交易方式回购已发行的人民币普通股（A股） 股票，回购的股份将全部用于注销以减少公司注册资本。本次回购的资 金总额不低于人民币10,000万元（含）且不超过人民币15,000万元（含）， 回购价格不超过人民币9.16元/股（含），具体回购股份的数量以回购 结束时实际回购的股份数量为准。回购期限为自公司股东大会审议通过 本次回购方案之日起12个月内。公司已在中国证券登记结算有限责任公 司深圳分公司开立股份回购专用证券账户。具体内容详见公司分别于 2024年4月26日和5月21日在《中国证券 ...

2025年3月29日，"2025公立医院高质量发展与智慧运营研讨会"在山东济南盛大举行，活动上正式启动了首都国际医学大会医疗科技创新转化专题活动。 专题活动由中国医院协会与北京金融科技研究院共同主办，以"创新驱动・融合发展：医疗科技赋能健康未来"为主题，致力于搭建医疗科技创新与产业转化 高效对接平台。 转自：新华财经 山东第一医科大学第二附属医院党委书记曹铭锋说："这一活动为我们医院与科研机构、企业之间的合作提供了新的契机，有助于推动医院的科研创新和临 床应用发展。"京东健康智慧医疗业务代表说："希望通过参与这个活动，我们的创新项目能够获得更多关注和支持，加速成果转化，为医疗健康事业贡献力 量。" 未来，首都国际医学大会医疗科技创新转化专题活动将按照既定计划有序推进，为推动我国医疗产业的升级和健康中国建设发挥积极作用。（熊琳，钟婧） 编辑：王菁 启动仪式上，中国医院协会常务副会长毛群安指出，医疗科技创新对于提升医疗服务水平、推动医疗产业升级具有至关重要的意义。当前，我国医疗科技领 域正处于快速发展阶段，需要各方力量共同努力，加速科研成果向临床应用和产业价值的转化。此次专题活动的启动，将为医疗科技企业、高校、科 ...